Clinical trials for Endometrial cancer

117 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Early Access Endometrial cancer

Accès précoce post-AMM - JEMPERLI (Dostarlimab)

Stage III Stage IV Locally Advanced Metastatic MSS/pMMR None 1

MSI/dMMR

GlaxoSmithKline

Early Access Endometrial cancer

Accès précoce post-AMM - JEMPERLI (Dostarlimab)

Stage III Stage IV Locally Advanced Metastatic MSI/dMMR None 1

GlaxoSmithKline

Phase 3 Endometrial cancer #NCT06952504 #2024-519331-42-00

[TroFuse-033] Étude comparant le SACITUZUMAB TIRUMOTECANen association avec le PEMBROLIZUMAB et le pembrolizumab seul chez des participantes atteintes d'un cancer de l'endomètre pMMR

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Locally Advanced Metastatic MSS/pMMR None Systemic Treatment-Naive

MSI/dMMR Immunotherapy Antibody Drug Conjugates (ADC) Immunotherapy Antibody Drug Conjugates (ADC)

Institut Bergonié (Bordeaux), Centre Léon Bérard (Lyon), Hôpital Cochin (Paris ), IUCT Oncopôle (Toulouse), Centre François Baclesse (Caen ) (and 5 more...)

Merck Sharp & Dohme LLC

Phase 3 Endometrial cancer #NCT06340568 #2023-507525-42-00

Étude clinique des effets anticancéreux d'un traitement expérimental ou d'une chimiothérapie chez des patientes atteintes d'un cancer de l'utérus récidivant

Cohorte 1 et 2

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Locally Advanced Metastatic HER2 None 1 Immunotherapy Chemotherapy Systemic Treatment-Naive Immunotherapy Chemotherapy

Antibody Drug Conjugates (ADC) Antibody Drug Conjugates (ADC)

Clinique Victor Hugo - Elsan (Le Mans), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)

BioNTech SE

Phase 3 Endometrial cancer #NCT06712472 #2023-503886-44-00

[RAINBO-RED] Essai randomisé de phase III comparant l'OLAPARIB d'entretien à l'observation après chimioradiothérapie adjuvante pour le cancer de l'endomètre P53abn

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Stage I Stage II Stage III Localized Locally Advanced TP53 None Surgery Chemotherapy Radiotherapy

MSI/dMMR POLE

Centre Antoine Lacassagne (Nice), Institut Paoli-Calmettes (Marseille), Institut Curie - Paris (Paris), Gustave Roussy (Villejuif), Centre Hospitalier d'Albi (Albi) (and 9 more...)

Gustave Roussy, Campus du cancer, Grand Paris

Phase 3 Endometrial cancer #NCT06989112 #2023-508056-19-00

[DESTINY-Endometrial01] Étude de phase III évaluant le TRASTUZUMAB DERUXTECAN associé au RILVEGOSTOMIG ou au PEMBROLIZUMAB comme traitement de première intention du cancer de l'endomètre exprimant HER2 (IHC 3+/2+) et capable de réparer les mésappariements (pMMR)

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Stage III Stage IV Locally Advanced Metastatic HER2 None Systemic Treatment-Naive

Immunotherapy Antibody Drug Conjugates (ADC) Immunotherapy Antibody Drug Conjugates (ADC)

Centre Antoine Lacassagne (Nice), Hôpital Privé des Côtes d'Armor (Plérin), IUCT Oncopôle (Toulouse)

Phase 3 Endometrial cancer #NCT05255653

[RAINBO- MMRd-GREEN] Affiner le traitement adjuvant du cancer de l'endomètre en fonction des caractéristiques moléculaires

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Other Stage IV Localized Locally Advanced MSI/dMMR None Surgery Surgery

POLE Systemic Treatment-Naive Immunotherapy Radiotherapy Systemic Treatment-Naive Immunotherapy Radiotherapy

Gustave Roussy (Villejuif)

Centre médical universitaire de Leyde

Phase 3 Endometrial cancer #NCT05078047

[MOIO] Étude comparant l'administration standard d'une immunothérapie (IO) vs la même IO administrée tous les 3 mois chez des patients en réponse après 6 mois d'IO standard

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Locally Advanced Metastatic Immunotherapy

Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Groupe Hospitalier Saint André (Bordeaux), Hôpital Cochin (Paris ), Centre Hospitalier Intercommunal Elbeuf - Louviers - Val de Reuil (Saint-Aubin-lès-Elbeuf), Centre Léon Bérard (Lyon) (and 25 more...)

UNICANCER

Phase 2 / Phase 3 Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03651206 #2024-516782-36-00

[ROCSAN] Carcinosarcome endométrial ou ovarien récurrent ANTI-PD1 NIRAPARIB

Other ovarian cancer Carcinosarcoma Other Localized Locally Advanced Metastatic None 1 2 3 or more Chemotherapy Chemotherapy

Immunotherapy Targeted therapy Immunotherapy Targeted therapy

Centre Eugene Marquis (Rennes), IUCT Oncopôle (Toulouse), Centre Léon Bérard (Lyon), Institut Curie - Paris (Paris), Groupe Hospitalier Diaconesses - Site Croix Saint Simon (Paris) (and 8 more...)

Groupe ARCAGY/GINÉCO

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06581432 #2023-510429-14-00

[Beamion PANTUMOR-1] Etude visant à déterminer si le zongertinib est bénéfique aux personnes atteintes de cancers avancés présentant des altérations du gène HER2

HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1 2 3 or more

Systemic Treatment-Naive

CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif)

Boehringer Ingelheim